Basel’s innovation campus is expanding with new research institutes, laboratories, and collaborative infrastructure for life sciences growth.
Johannes Eisenhut
Advertisement
Johannes Eisenhut, PhD, is CEO of SENN Development.
Articles by Johannes Eisenhut
Flexible laboratory and good manufacturing practice-ready infrastructure in Basel is designed to support biopharma startups, manufacturing scale-up, and innovation growth, says SENN Development CEO Dr. Johannes Eisenhut.
SENN Development CEO Dr. Johannes Eisenhut discusses how Basel’s expanding life sciences ecosystem supports biopharma innovation through research infrastructure and specialized talent growth.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Regeneron's Libtayo Earns CHMP Nod for Expanded EU Dosing
2
Roche, Hansoh Sign Second ADC Pact Covering Preclinical and Roche-Selected Targets
3
Biomarker Testing Gaps Can Stall Targeted Oncology Therapy, BMS’s Dr Pennell Says
4
Lilly’s Omvoh Reaches 50% One-Year Remission in Pediatric Ulcerative Colitis
5